We used a multi-step strategy to identify novel therapeutic targets in ovarian cancer cells that induce cell death and might improve taxane-based effects: (1) screening of 711 pools of siRNAs (Dharmacon kinome library) targeting individual human kinases; (2) specific hits were validated using single siRNAs (cherry picking) that made up the pool in the primary screening; and (3) assays for cell viability, cell death (Caspase-3/7 activity, Annexin staining) and cell cycle distribution (FACS measurements) of siRNA-treated OVCAR-3 cells (Supplementary Figure 2A). The gene discussed is CASP3; the disease is ovarian cancer.